Search Results | Blood | American Society of Hematology

1-20 of 99

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Blood (2021) 138 (24): 2469–2484.

DOI: https://doi.org/10.1182/blood.2021011898

Published: 2021

Includes: Supplemental data

Journal Articles

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Meredith J. McAdams, Mustafa Hyder, Dimana Dimitrova, Jennifer L. Sadler, Christi McKeown, Seth M. Steinberg, Amy Chai, Scott Napier, Anita Stokes, Jennifer Sponaugle, Thomas E. Hughes, Nu Ri Cha, Jennifer Cuellar-Rodriguez, Melissa Walker, Ronald E. Gress, Jennifer A. Kanakry, Christopher G. Kanakry

Blood (2021) 138 (Supplement 1): 101.

DOI: https://doi.org/10.1182/blood-2021-146997

Published: 2021

Journal Articles

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Elif Yilmaz, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, James D. Phelan, Sarah Evans, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson, Mark Roschewski, Christopher Melani

Blood (2021) 138 (Supplement 1): 4504.

DOI: https://doi.org/10.1182/blood-2021-151824

Published: 2021

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

Blood (2021) 138 (Supplement 1): 3537.

DOI: https://doi.org/10.1182/blood-2021-147032

Published: 2021

Journal Articles

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Blood (2021) 138 (Supplement 1): 524.

DOI: https://doi.org/10.1182/blood-2021-145228

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

DOI: https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea Nicole Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson, Mark Roschewski

Blood (2021) 138 (Supplement 1): 453.

DOI: https://doi.org/10.1182/blood-2021-147451

Published: 2021

Journal Articles

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Sara K. Silbert, Elizabeth M. Holland, Seth M. Steinberg, Lauren Little, Toni Foley, Haneen Shalabi, Bonnie Yates, Nirali N. Shah

Blood (2021) 138 (Supplement 1): 1731.

DOI: https://doi.org/10.1182/blood-2021-146979

Published: 2021

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

DOI: https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

DOI: https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Kathryn Lurain, Thomas S. Uldrick, Ramya Ramaswami, Mark N. Polizzotto, Priscila H. Goncalves, Anaida Widell, Seth M. Steinberg, Elaine S. Jaffe, Stefania Pittaluga, Hao-Wei Wang, Constance M. Yuan, Mary Anne Tamula, Staci Martin, Pamela L. Wolters, Jomy George, Richard F. Little, Robert Yarchoan

Blood (2020) 136 (19): 2229–2232.

DOI: https://doi.org/10.1182/blood.2020006048

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

DOI: https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Jagan R. Muppidi, MD PhD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Lydia L. Chou, CRNP, Sarah Evans, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-134115

Published: 2020

Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-137709

Published: 2020

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 12–13.

DOI: https://doi.org/10.1182/blood-2020-137637

Published: 2020

Journal Articles

A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Alen Ostojic, MD, Noa G. Holtzman, MD, Lauren M. Curtis, MD, Brian C. Shaffer, MD, Jeffrey S Rubin, MD PhD, Frances T. Hakim, PhD, Jacqueline W Mays, DDS, PhD, Theo Heller, MD, Edward W Cowen, MD, Sabine Werner, PhD, Michael Emanuel, BSN, RN, Seth M. Steinberg, PhD, Ronald E. Gress, MD, Steven Z. Pavletic, MD MS

Blood (2020) 136 (Supplement 1): 21.

DOI: https://doi.org/10.1182/blood-2020-140059

Published: 2020

Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan

Blood (2020) 135 (25): 2316–2319.

DOI: https://doi.org/10.1182/blood.2019004602

Published: 2020

Includes: Supplemental data

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

DOI: https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

Dana Schaar, Filip Pirsl, Seth M. Steinberg, PhD, Laura Parsons-Wandell, Michael Emanuel, Shaneil Flucker, Jeannette Nashed, Claire Ruben, Lauren M. Curtis, MD, Edward W Cowen, MD, Jacqueline Mays, PhD DDS, Pashna N. Munshi, MD, Annie Im, MD, Ann Berger, MD, Galen O Joe, MD, Manuel B Datiles, III, MD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 4558.

DOI: https://doi.org/10.1182/blood-2019-124020

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

DOI: https://doi.org/10.1182/blood-2019-122070

Published: 2019

2 3 4 5

NARROW

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only